drugset
drugset / Trial / NCT05931328

The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

NCT05931328 ↗

Phase 2 Recruiting 28 enrolled The First Affiliated Hospital with Nanjing Medical University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the efficacy and safety of the combination of thiotepa and pomalidomide in the treatment of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL).

Timeline

Start
2022-10-15
Primary completion
2024-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pomalidomide Other / unclassified 12 mg Oral
Subject Thiotepa Other / unclassified 30 mg/m2 Intravenous

Indications

primary central nervous system lymphoma